What is MET Mutation Cancer?
MET is a tyrosine kinase signaling pathway that encodes the hepatocyte growth factor receptor protein. In healthy cells, this pathway helps with cell survival, motility, and mitosis. When there is an amplification of MET, the cells are involved in proliferation, invasion, angiogeneis, and metastasis. This can cause the cancer cells to reproduce and spread more quickly than cancers without an oncogene driver.
The most common cancer types with the MET mutation are not limited to but include:
- Lung Adenocarcinoma
- Colon Adenocarcinoma
- Cutaneous Melanoma
- Endometrial Endometrioid Adenocarcinoma
- Breast Invasive Ductal Carcinoma
MET Mutation Cancer Symptoms
The symptoms of cancers with MET mutations depend on the specific cancer type. However, cancers that are positive for a MET mutation are known to be more aggressive and have a worse prognosis than cancers without the amplification.
What Causes MET Mutation Cancer?
Unlike some mutations, MET is not inherited from an individual’s family. The mutation develops over the patient’s lifetime and the exact cause is unknown.
MET Mutation Cancer Treatment
Targeted therapies are available for cancer patients with a MET amplification. The most common drugs used are:
Because non-small cell lung cancer is the most common cancer type to have a mutation in the MET gene (5% of all cases), it has the most treatments available. However, clinical trials are continuously evaluating new therapies targeting MET mutations.
MET Mutation Cancer Clinical Trials
There are approximately 52 cancer clinical trials that are recruiting patients with MET amplifications and mutations currently in the United States. With such an extensive list, many of them could be beneficial for you. Our team of patient advocates, who are oncology nurses, combined with Massive Bio’s Artificial Intelligence based Clinical Trial Matching System will find the best option for you.
With just a few clicks, you can see your clinical trial matches now. Click here to use our AI-powered Clinical Trial Matching System.
How Do We Help MET mutation Cancer Patients?
Massive Bio’s initial cancer treatment consultation, as well as our clinical trial matching service, is free for patients with MET amplifications and mutations. Our patient advocates work closely with patients to gather information regarding their current medical status, and then will provide a list of options from available cancer clinical trials close to your home.
We can also provide a comprehensive case analysis through our Virtual Tumor Board of top cancer specialists. The Virtual Tumor Board (VTB) is comprised of highly specialized oncologists from nationally-recognized Cancer Centers of Excellence. Within just 7-10 days after receiving your medical records, Massive Bio can provide you with a treatment plan that can be executed without having to travel far distances or use your valuable time.